Key facts
- This page summarizes Slate Path Capital LP's Form 4 filing for Cyclerion Therapeutics, Inc. (CYCN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Nov 2024, 16:05.
Slate Path Capital LP - 21 Nov 2024 Form 4 Insider Report for Cyclerion Therapeutics, Inc. (CYCN)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- CYCN
- Reported as of
- 21 Nov 2024
- Net transaction value
- -$555,108
- SEC form
- 4
- Accepted by SEC
- 25 Nov 2024, 16:05:30 UTC
- Prior SEC filing
- 07 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- Slate Path Capital LP, By: Jades GP, LLC, its General Partner, By: /s/ John Metzner, its Chief Operating Officer
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Slate Path Capital LP filed Form 4 for Cyclerion Therapeutics, Inc. (CYCN) on 25 Nov 2024.
Change
- Previous filing in this sequence was filed on 07 Jun 2021.
- Current net transaction value: -$555,108.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYCN
transaction
Common Stock, no par value
Sale
- Transaction value
- $555,108
- Shares
- -357,880
- Change %
- -100%
- Price
- $1.55
- Shares after
- 0
- Date
- 21 Nov 2024
- Ownership
- See footnote
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Slate Path Capital LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The number of shares reported herein reflect the one-for-twenty reverse stock split effected by the Issuer on May 15, 2023.
Footnote F2
The securities to which this filing relates were held by certain funds (the "Slate Path Funds"). Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership acts as the investment manager of the Slate Path Funds. Mr. David Greenspan serves as the managing member of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager. The filing of this statement shall not be deemed an admission that either Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
SEC remarks
The Power of Attorney dated as of July 31, 2020 executed by David Greenspan authorizing Jim Feeney to sign and file this form on his behalf is attached as Exhibit 24.1 to the Reporting Persons Form 3 with respect to the Issuer filed with the Securities and Exchange Commission on August 10, 2020.